Nexeon MedSystems Inc. announced its completion of an initial series of clinical studies evaluating the utilization of transcutaneous auricular vagus nerve stimulation (aVNS) for the relief of paroxysmal atrial fibrillation. The Company was previously awarded a €3.4M research grant in relation to this study from the Walloon Region government of Belgium in coordination with the region's health competitiveness cluster BioWin. Next steps related to this clinical program will be the completion of a study on twenty patients suffering from paroxysmal atrial fibrillation. The protocol includes an assessment of therapeutic safety and feasibility while participants receive chronic aVNS. VNS has been used for years to treat epilepsy. Researchers worldwide are investigating whether delivering pulses of electricity to the nerve can help treat tinnitus, stroke, headache, asthma, obesity, depression, Crohn's disease, and more.